Genertec Universal Medical Group Toekomstige groei
Future criteriumcontroles 1/6
Genertec Universal Medical Group is forecast to grow earnings and revenue by 6.8% and 7.5% per annum respectively. EPS is expected to grow by 5.8% per annum. Return on equity is forecast to be 11.8% in 3 years.
Belangrijke informatie
6.8%
Groei van de winst
5.8%
Groei van de winst per aandeel
| Diversified Financial winstgroei | 26.4% |
| Inkomstengroei | 7.5% |
| Toekomstig rendement op eigen vermogen | 11.8% |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 13 Sep 2024 |
Recente toekomstige groei-updates
Recent updates
Earnings Working Against Genertec Universal Medical Group Company Limited's (HKG:2666) Share Price
Oct 09
Genertec Universal Medical Group's (HKG:2666) Shareholders Will Receive A Bigger Dividend Than Last Year
May 22Genertec Universal Medical Group Company Limited's (HKG:2666) Price Is Right But Growth Is Lacking
May 10Why Investors Shouldn't Be Surprised By Genertec Universal Medical Group Company Limited's (HKG:2666) Low P/E
Feb 05Genertec Universal Medical Group (HKG:2666) Is Reducing Its Dividend To CN¥0.34
Jun 08Genertec Universal Medical Group's (HKG:2666) Shareholders Will Receive A Bigger Dividend Than Last Year
Jun 08Genertec Universal Medical Group's (HKG:2666) Shareholders Will Receive A Bigger Dividend Than Last Year
Mar 31Should You Be Adding Genertec Universal Medical Group (HKG:2666) To Your Watchlist Today?
Aug 20Here's Why We Think Genertec Universal Medical Group (HKG:2666) Is Well Worth Watching
Apr 19Shareholders Of Genertec Universal Medical Group (HKG:2666) Must Be Happy With Their 34% Return
Mar 10Is Genertec Universal Medical Group Company Limited (HKG:2666) Trading At A 48% Discount?
Feb 19Did Genertec Universal Medical Group Company Limited (HKG:2666) Insiders Buy Up More Shares?
Feb 01
The Case For Genertec Universal Medical Group Company Limited (HKG:2666): Could It Be A Nice Addition To Your Dividend Portfolio?
Jan 11What Kind Of Investors Own Most Of Genertec Universal Medical Group Company Limited (HKG:2666)?
Dec 21Reflecting on Genertec Universal Medical Group's (HKG:2666) Share Price Returns Over The Last Three Years
Nov 30Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 15,928 | 2,457 | 3,490 | 4,549 | 2 |
| 12/31/2025 | 15,133 | 2,322 | 2,619 | 3,597 | 3 |
| 12/31/2024 | 14,049 | 2,197 | 2,346 | 3,324 | 3 |
| 6/30/2024 | 13,203 | 2,061 | 5,224 | 6,385 | N/A |
| 3/31/2024 | 13,311 | 2,041 | 4,661 | 5,690 | N/A |
| 12/31/2023 | 13,419 | 2,021 | 4,097 | 4,994 | N/A |
| 9/30/2023 | 13,161 | 1,960 | 1,623 | 2,479 | N/A |
| 6/30/2023 | 12,797 | 1,896 | -823 | -12 | N/A |
| 3/31/2023 | 12,264 | 1,892 | 296 | 1,010 | N/A |
| 12/31/2022 | 11,730 | 1,888 | 1,414 | 2,032 | N/A |
| 9/30/2022 | 11,018 | 1,882 | 1,169 | 1,682 | N/A |
| 6/30/2022 | 10,305 | 1,875 | 923 | 1,333 | N/A |
| 3/31/2022 | 9,936 | 1,855 | -431 | -34 | N/A |
| 12/31/2021 | 9,567 | 1,835 | -1,786 | -1,401 | N/A |
| 9/30/2021 | 9,371 | 1,870 | -3,883 | -3,520 | N/A |
| 6/30/2021 | 9,175 | 1,904 | -5,980 | -5,640 | N/A |
| 3/31/2021 | 8,709 | 1,776 | -3,676 | -3,306 | N/A |
| 12/31/2020 | 8,243 | 1,648 | -1,373 | -972 | N/A |
| 9/30/2020 | 7,843 | 1,559 | 848 | 1,212 | N/A |
| 6/30/2020 | 7,444 | 1,470 | 3,070 | 3,397 | N/A |
| 3/31/2020 | 7,095 | 1,479 | 519 | 786 | N/A |
| 12/31/2019 | 6,747 | 1,489 | -2,032 | -1,824 | N/A |
| 9/30/2019 | 6,071 | 1,459 | -4,512 | -4,367 | N/A |
| 6/30/2019 | 5,395 | 1,429 | -6,991 | -6,909 | N/A |
| 3/31/2019 | 4,845 | 1,390 | -6,369 | -6,319 | N/A |
| 12/31/2018 | 4,295 | 1,352 | -5,746 | -5,729 | N/A |
| 9/30/2018 | 4,080 | 1,329 | -6,215 | -6,198 | N/A |
| 6/30/2018 | 3,865 | 1,305 | -6,683 | -6,667 | N/A |
| 3/31/2018 | 3,645 | 1,227 | N/A | -5,870 | N/A |
| 12/31/2017 | 3,424 | 1,149 | N/A | -5,072 | N/A |
| 9/30/2017 | 3,267 | 1,105 | N/A | -4,400 | N/A |
| 6/30/2017 | 3,111 | 1,062 | N/A | -3,729 | N/A |
| 3/31/2017 | 2,910 | 967 | N/A | -3,055 | N/A |
| 12/31/2016 | 2,709 | 872 | N/A | -2,382 | N/A |
| 9/30/2016 | 2,587 | 825 | N/A | -2,577 | N/A |
| 6/30/2016 | 2,464 | 778 | N/A | -2,773 | N/A |
| 3/31/2016 | 2,330 | 718 | N/A | -3,613 | N/A |
| 12/31/2015 | 2,195 | 659 | N/A | -4,452 | N/A |
| 9/30/2015 | 2,031 | 605 | N/A | -4,702 | N/A |
| 6/30/2015 | 1,866 | 551 | N/A | -4,951 | N/A |
| 3/31/2015 | 1,711 | 504 | N/A | -4,531 | N/A |
| 12/31/2014 | 1,557 | 457 | N/A | -4,111 | N/A |
| 12/31/2013 | 984 | 313 | N/A | -4,119 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: 2666's forecast earnings growth (6.8% per year) is above the savings rate (2.3%).
Winst versus markt: 2666's earnings (6.8% per year) are forecast to grow slower than the Hong Kong market (11.5% per year).
Hoge groeiwinsten: 2666's earnings are forecast to grow, but not significantly.
Omzet versus markt: 2666's revenue (7.5% per year) is forecast to grow slower than the Hong Kong market (7.8% per year).
Hoge groei-inkomsten: 2666's revenue (7.5% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: 2666's Return on Equity is forecast to be low in 3 years time (11.8%).